This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.

Browse

Novolin R (Regular Human Insulin)

Cheap OTC short-acting insulin used by bodybuilders post-workout for "nutrient partitioning" — claimed to drive glucose, amino acids, and creatine into muscle.

Aliases (5)

Humulin R · regular insulin · R · slin · short-acting insulin

TYPICAL DOSE

0.5-1 IU/kg/day total split

TID with meals

ROUTE

—

CYCLE

—

STORAGE

—

Overview

What is Novolin R (Regular Human Insulin)?

Novolin R is a recombinant human regular insulin (short-acting) used to control blood glucose in type 1 and type 2 diabetes. It is identical in amino acid sequence to endogenous human insulin, manufactured in yeast.

Key Benefits

Provides postprandial glucose control in diabetic patients and is used in DKA management, hyperkalemia treatment, and ICU glucose protocols. Off-label in athletic/bodybuilding contexts (high-risk) for nutrient partitioning and anabolic effects.

Mechanism of Action

Binds the insulin receptor (IR), a transmembrane receptor tyrosine kinase, triggering autophosphorylation and downstream IRS/PI3K/Akt signaling. This activates GLUT4 translocation in muscle and adipose tissue, glycogen synthesis, lipogenesis, and protein synthesis while inhibiting gluconeogenesis.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

Peptide Interactions

In bodybuilding context (DO NOT REPLICATE):

Synergistic

Often stacked with HGH, IGF-1, AAS for "GH-insulin-AAS triad." Compounds risk dramatically.

Beta blockers

Avoid

(mask hypoglycemia symptoms — life-threatening combo)

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Side Effects & Safety

Common (in all users): Hypoglycemia symptoms if mistimed
Less common: Injection-site lipohypertrophy
Rare-serious — and the entire reason for SKIP-PERMANENT:
- Severe hypoglycemia → coma → death. Multiple documented bodybuilder deaths (Ghent Wakefield 1998 case series and many since). Brain injury possible from prolonged hypoglycemia even if not fatal.
- Iatrogenic insulin reaction during sleep — bodybuilders who dose evening then nap have died because hypoglycemia symptoms don't wake them.
- Counter-regulation failure — repeated hypoglycemia blunts glucagon response, making subsequent episodes more dangerous (hypoglycemia unawareness).
- Long-term: Insulin promotes adipose lipogenesis and is mitogenic at high doses — chronic supraphysiologic insulin exposure may increase cancer risk (epidemiologic, debated).
- Edema, hypokalemia at higher doses (insulin shifts K+ intracellularly).
Specific watch periods: Every dose. There is no safe interval.